Regulation of Formation and Proposed Structure of the Factor Inhibiting the Release of Melanocyte-stimulating Hormone

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1971 Jul 1

PMID 5283931

Citations 23

Authors

M E Celis

S Taleisnik

R Walter

Affiliations

Soon will be listed here.

Abstract

Microsomal preparations from the stalk median eminence of female rats are shown to contain an enzymic activity that is responsible for the formation of MSH-release-inhibiting factor (MSH-R-IF). The amount of this activity remains constant throughout the estrous cycle. The corresponding mitochondrial preparations from the stalk median eminence contain another enzymic principle, estrous cycle-dependent, which competes with the enzyme present in the microsomal preparation for the same "substrate", and can thereby prevent the formation of MSH-R-IF. Several neurohypophyseal hormones, analogs, and peptide intermediates have been tested for their intrinsic MSH-R-IF activity and for their ability to be transformed into MSH-R-IF by incubation with microsomal preparations of stalk median eminence from male rats; it is concluded that the enzyme responsible for the formation of MSH-R-IF is an exopeptidase and that the release-inhibiting factor itself is a tripeptide. Oxytocin is converted by the incubation to (L)-prolyl-(L)-leucylglycinamide; nanogram amounts of this tripeptide inhibit the release of MSH from the pituitary both in vivo and in vitro.

Citing Articles

Roots and early routes of neuroendocrinology.

Rodriguez E, Guerra M, Blazquez J Cell Tissue Res. 2025; .

PMID: 39883141 DOI: 10.1007/s00441-024-03928-0.

Stapling Amantadine to Melanostatin Neuropeptide: Discovery of Potent Positive Allosteric Modulators of the D Receptors.

Silva-Reis S, Correia X, Costa-Almeida H, Pires-Lima B, Maronde D, Costa V ACS Med Chem Lett. 2023; 14(12):1656-1663.

PMID: 38116429 PMC: 10726482. DOI: 10.1021/acsmedchemlett.3c00264.

In vitro permeation of micronized and nanonized alaptide from semisolid formulations.

Opatrilova R, Cernikova A, Coufalova L, Dohnal J, Jampilek J ScientificWorldJournal. 2014; 2013:787283.

PMID: 24453907 PMC: 3881672. DOI: 10.1155/2013/787283.

Mass spectrometric quantification of MIF-1 in mouse brain by multiple reaction monitoring.

Kheterpal I, Kastin A, Mollah S, Yu C, Hsuchou H, Pan W Peptides. 2009; 30(7):1276-81.

PMID: 19540426 PMC: 3521590. DOI: 10.1016/j.peptides.2009.04.004.

Plasma beta-lipotropin levels in Parkinson's disease.

Wiesen M, Yahr M, Krieger D J Neural Transm. 1982; 53(1):75-82.

PMID: 6278076 DOI: 10.1007/BF01243521.

References

MERRIFIELD R . Automated synthesis of peptides. Science. 1965; 150(3693):178-85. DOI: 10.1126/science.150.3693.178. View

Ferrier B, Jarvis D, DU VIGNEAUD V . Deamino-oxytocin. Its isolation by partition chromatography on Sephadex and crystallization from water, and its biological activities. J Biol Chem. 1965; 240(11):4264-6. View

Brooks C, Ishikawa T, Koizumi K, Lu H . Activity of neurones in the paraventricular nucleus of the hypothalamus and its control. J Physiol. 1966; 182(1):217-31. PMC: 1357467. DOI: 10.1113/jphysiol.1966.sp007820. View

DU VIGNEAUD V, FLOURET G, Walter R . Synthesis and some biological properties of 4-valine-oxytocin and 1-deamino-4-valine-oxytocin. J Biol Chem. 1966; 241(9):2093-6. View

Taleisnik S, Tomatis M . Antagonistic effect on melanocyte-stimulating hormone release of two neural tissue extracts. Am J Physiol. 1967; 212(1):157-63. DOI: 10.1152/ajplegacy.1967.212.1.157. View

Ferrier B, DU VIGNEAUD V . 9-Deamidooxytocin, an analog of the hormone containing a glycine residue in place of the glycinamide residue. J Med Chem. 1966; 9(1):55-7. DOI: 10.1021/jm00319a014. View

Kastin A, Schally A . MSH activity in pituitaries of rats treated with hypothalamic extracts. Gen Comp Endocrinol. 1966; 7(3):452-6. DOI: 10.1016/0016-6480(66)90066-9. View

Taleisnik S, Tomatis M . Melanocyte-stimulating hormone-releasing and inhibiting factors in two hypothalamic extracts. Endocrinology. 1967; 81(4):819-25. DOI: 10.1210/endo-81-4-819. View

Taleisnik S, De Olmos J, ORIAS R, Tomatis M . Effect of hypothalamic lesions on pituitary melanocyte-stimulating hormone. J Endocrinol. 1967; 39(4):485-92. DOI: 10.1677/joe.0.0390485. View

10.

Meienhofer J, Sano Y . A solid-phase synthesis of [lysine]-vasopressin through a crystalline protected nonapeptide intermediate. J Am Chem Soc. 1968; 90(11):2996-7. DOI: 10.1021/ja01013a067. View

11.

Himmelhoch R, Peterson E . Preparation of leucine aminopeptidase free of endopeptidase activity. Biochemistry. 1968; 7(6):2085-93. DOI: 10.1021/bi00846a010. View

12.

Tomatis M, Taleisnik S . Pituitary melanocyte-stimulating hormone and its hypothalamic factors during the estrous cycle. Acta Physiol Lat Am. 1968; 18(1):96-101. View

13.

Sawyer W, Wuu T, BAXTER J, Manning M . 4-Proline analogues of neurohypophysial hormones: hypothetical intermediates in peptide evolution. Endocrinology. 1969; 85(2):385-8. DOI: 10.1210/endo-85-2-385. View

14.

BAXTER J, Wuu T, Manning M, Sawyer W . Solid phase synthesis and some pharmacological properties of 8-glutamine-oxytocin: a possible intermediate in the evolution of the neurohypophysial hormones. Experientia. 1969; 25(11):1127-8. DOI: 10.1007/BF01900225. View

15.

Burgus R, Dunn T, Desiderio D, Ward D, Vale W, Guillemin R . Biological activity of synthetic polypeptide derivatives related to the structure of hypothalamic TRF. Endocrinology. 1970; 86(3):573-82. DOI: 10.1210/endo-86-3-573. View

16.

Bowers C, Schally A, Enzmann F, Boler J, Folkers K . Porcine thyrotropin releasing hormone is (pyro)glu-his-pro(NH2). Endocrinology. 1970; 86(5):1143-53. DOI: 10.1210/endo-86-5-1143. View

17.

Glass J, Dubois B, SCHWARTZ I, Walter R . Inactivation of neurohypophyseal peptides by a uterine enzyme. Characterization of the hydrolytic cleavage. Endocrinology. 1970; 87(4):730-7. DOI: 10.1210/endo-87-4-730. View

18.

Sawyer W, BAXTER J, Manning M, Heinicke E, PERKS A . A fraction resembling oxytocin from Squalus acanthias: pharmacological comparisons with synthetic peptides. Gen Comp Endocrinol. 1970; 15(1):52-8. DOI: 10.1016/0016-6480(70)90096-1. View

19.

Yamanaka T, Hase S, Sakakibara S, SCHWARTZ I, Dubois B, Walter R . Crystalline deamino-dicarba-oxytocin. Preparation and some pharmacological properties. Mol Pharmacol. 1970; 6(5):474-80. View

20.

Meienhofer J, Trzeciak A, Havran R, Walter R . A solid-phase synthesis of (8-arginine)-vasopressin through a crystalline protected nonapeptide intermediate and biological properties of the hormone. J Am Chem Soc. 1970; 92(24):7199-202. DOI: 10.1021/ja00727a031. View